Ph. D Jeanmarie Guenot is a pharmaceutical expert who is dedicated to researching causes and treatments to multiple blood-borne illnesses such as autoimmune diseases and cancers. She is the CEO and President of Amphivera Therapeutics, a company that is responsible for developing and innovating new antibody treatments for these diseases. Despite her 20 years working in the medical field at https://www.takeda.com/news/2017/20170111_7659.html, she also has considerable experience in business and venture capitalism which makes her a perfect all-around role for wherever she may be situated.
Guenot work with Amphivera Therapeutics is perhaps the most interesting due to the nature of the work and the implications it can have on the future of medicine. The research done by the company is aimed at treating hematological cancers and diseases, such as leukemia. In fact, the company is responsible for developing the CD3 and AMV-364 which are used for treating myeloid leukemia. If left untreated, this disease can be fatal in a few short months, due to the rapid growth and spread of cancer cells in the bone marrow. However, with the development of drugs at Amphivera, this disease can become so much more treatable in the near future.
Dr. Jeanmarie Guenot also had a vital role at PDL Biopharma, where she was the Vice President in charge of licenses, as well as profits and losses. She was responsible for giving a license to biopharmaceutical company Ophthotech for an ophthalmic indication on a new oncology drug. She also was a part of a collaborative $800 million deal between PDL and Biogen that was to test certain cancer-fighting drugs on BusinessWire.com. The deal required several autoimmune drug candidates, as well as three Stage 2 cancer patients.
Utilizing the services provided by Amphivena Therapeutics means that people with deadly blood-borne cancers can have a second chance at life again. Mentioned on amphivena.com, the drugs developed within the company are fully researched to be safe while also being effective. As early as 20 years ago, we would not have had the technologies that we do today, and medical advancements are always being made. Soon, with the help of companies like Amphivena, diseases like cancer and leukemia will have an even lower mortality rate.